Filing Flows › Caris Life Sciences (CAI) › Q2 2025
Caris Life Sciences (CAI) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 12, 2025
Caris Life Sciences (CAI) reported revenue of $181M for the second quarter 2025 (Q2 2025), +81% from a year earlier and +50% from the quarter before. Operating margin was -9.9%, net loss $71.8M (39.6% of revenue).
Caris Life Sciences, Q2 2025: revenue $181M (+81% year over year), operating margin -9.9%, net loss $71.8M, operating cash flow $7.3M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $181M | +50% | +81% |
| Operating profit | −$18.0M | — | — |
| Net earnings | −$71.8M | — | — |
| Operating cash flow | $7.3M | — | — |
| Free cash flow | $5.9M | — | — |
What changed
Revenue was $181.4M in Q2 2025, up 81% year over year and up 50% from the previous quarter. Molecular Profiling Services was the largest line at 90% of revenue. Molecular Profiling Services added $75.3M year over year (up 86%), 93% of the total change.
Operating costs exceeded revenue by $18.0M, an operating margin of -9.9%. Total costs grew 19% against revenue growth of 81%. The fastest-growing cost line was General & admin (+57%). The quarter ended with a net loss of $71.8M, narrower than the previous quarter's $102.6M loss. Net interest and other expense of $53.8M was the main reason.
Operating cash flow was $7.3M. Non-cash charges added back $6.4M of depreciation and amortization and $28.3M of share-based compensation. Working capital and other items added $44.4M. After purchases of property and equipment ($1.4M), free cash flow as the company reports it was $5.9M.
Questions
What was Caris Life Sciences' revenue in the second quarter 2025?
Caris Life Sciences (CAI) reported revenue of $181M for the second quarter 2025 (Q2 2025), +81% from a year earlier and +50% from the quarter before.
Was Caris Life Sciences profitable in the second quarter 2025?
Operating loss was $18.0M (-9.9% of revenue) and net loss $71.8M.